Clinical TrialID 7976

Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose

NCT05809271

Healthy

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
7976
Evidence Id
7976
Core Evidence Id
7976
Source Clinical Trial Id
7971
Herb2 Clinical Trial Id
HBCT007971
Nct Id
NCT05809271
Title
Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose
Status
Recruiting
Phase
Phase 1
Study Result
No
Study Condition
Healthy
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
Intervention
DRUG: MDMA 120 mg + MDMA 60 mg|DRUG: MDMA 120 mg + placebo|DRUG: Placebo
Intervention Allocation
Randomized
Intervention Model
Crossover
Intervention Mask
Triple
Intervention Purpose
Basic_Science
Gender
All
Age
Adult, Older_Adult
Enrollment
24
Outcome Measure
Subjective effect duration for "any drug effect", Assessed by visual analog scale (VAS) using 10% of the individual maximal subjective response (Emax) as threshold for the onset and offset., Every 15 minutes for 9 hours after substance administration
Sponsor Collaborator
University Hospital, Basel, Switzerland
Funded By
OTHER
Location
University Hospital, Basel, 4031, Switzerland
Other Id
BASEC 2023-00167
Start Date
2023-11-17
Primary Completion Date
2025-12-31
Completion Date
2025-12-31
First Posted
2023-04-12
Results First Posted
Last Update Posted
2023-11-21
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05809271
Title Cn
Title En
Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose
Bilingual Status
semi_complete